Table 3 Clinical characteristics of the patients before and after BT

No. of patients

27

27

_

Total serum IgE KU/l, median [IQR]

65 [30–160]

87 [27–272]

0.2552

Blood eosinophil count cells/µl, median [IQR]

140 [20–410]

340 [120–640]

0.1533

Lung function, pre-bronchodilator

FEV₁%,median [IQR]

71 [63–94]

67 [59–87]

0.0179

 FEV₁ l, median [IQR]

2.43 [1.86–3.22]

1.97 [1.5–2.68]

0.0103

 FVC %, median [IQR]

99 [89–114]

86 [77–102]

0.0011

 FVC l, median [IQR]

3.62 [2.90–4.62]

3.19 [2.57–3.89]

0.0051

Asthma concomitant medication

 Oral corticosteroid-prednisone or the equivalent mg, median [IQR]

20 [5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25]

5 [0–12.5]

 < 0.0001

 Patients taking OCS, n (%)

24 (89)

15 (55)

0.0058

 Patients taking LAMA, n (%)

12 (44)

21 (77)

0.0244

 Patients taking LTRA, n (%)

10 (37)

6 (22)

1

 Patients taking theophylline, n (%)

4 (15)

0 (0)

0.1110

Assigned adapted GINA* step

 Step 4, n (%)

2 (7)

3 (11)

1

 Step 5, n (%)

25 (93)

24 (89)

1

Asthma control

 Exacerbations/y, median [IQR]

6 [3,4,5,6,7,8,9,10]

2 [1,2,3]

 < 0.0001

 ED visits/hospitalizations/y, median [IQR]

0 [0–1]

0 [0–0]

0.0022

Patient reported outcomes

 AQLQ score, median [IQR]

2.6 [2.1–3.0]

5.5 [4.4–6.0]

 < 0.0001

 ACQ score, median [IQR]

3.8 [3.2–4.6]

1.6 [1.2–2.0]

 < 0.0001